Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.44 |
| ▸ | FABP7 | O15540 | 1/20 | 0.42 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | CASP3 | P42574 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3208722 | 0.91 | EPHX2 (0.67) | EPHX2KDM4EMAPTALDH1A1KMT2A | |
| SCHEMBL15711868 | 0.89 | EPHX2 (0.65) | EPHX2KDM4EMAPTALDH1A1KMT2A | |
| SCHEMBL569486 | 0.85 | EPHX2 (0.60) | EPHX2ALDH1A1KMT2APOLBFABP5 | |
| SCHEMBL3581504 | 0.82 | EPHX2 (0.58) | EPHX2MAPTALDH1A1KMT2AMEN1 | |
| SCHEMBL8366872 | 0.82 | EPHX2 (0.75) | EPHX2MAPTALDH1A1KMT2AMEN1 | |
| SCHEMBL2648379 | 0.81 | EPHX2 (0.64) | EPHX2KDM4EMAPTKMT2AHSD17B10 | |
| SCHEMBL118052 | 0.81 | EPHX2 (0.63) | EPHX2ALDH1A1KMT2AFABP7FABP5 | |
| SCHEMBL29401210 | 0.81 | EPHX2 (0.63) | EPHX2ALDH1A1KMT2AFABP7FABP5 | |
| SCHEMBL29561956 | 0.81 | EPHX2 (0.63) | EPHX2ALDH1A1KMT2AFABP7FABP5 | |
| SCHEMBL17151439 | 0.81 | EPHX2 (0.74) | EPHX2KMT2AFABP7FABP5CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 235 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9682123-B2 | Methods of treating metabolic disease | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2017-06-20 | — | — | US | disclosed |
| US-20150190466-A1 | METHODS OF TREATING METABOLIC DISEASE | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2015-07-09 | — | — | US | disclosed |
| WO-2014068506-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF AUTOIMMUNE DISEASES | KANDULA MAHESH (IN) | 2014-05-08 | — | — | WO | disclosed |
| US-20130160150-A1 | METHODS FOR IDENTIFYING COMPOUNDS THAT MODULATE LISCH-LIKE PROTEIN OR C1ORF32 PROTEIN ACTIVITY AND METHODS OF USE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2013-06-20 | — | — | US | disclosed |
| US-8460880-B2 | Compositions, splice variants and methods relating to ovarian specific genes and proteins | DIADEXUS, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| CN-101238137-B | Derivatives of 4-or 5-aminosalicylic acid | ANTIBE THERAPEUTICS INC | 2012-05-02 | — | — | CN | disclosed |
| US-8114858-B2 | Derivatives of 4- or 5-aminosalicylic acid | ANTIBE THERAPEUTICS INC. (CA) | 2012-02-14 | — | — | US | disclosed |
| US-8114857-B2 | Derivatives of 4- or 5-aminosalicylic acid | ANTIBE THERAPEUTICS INC. (CA) | 2012-02-14 | — | — | US | disclosed |
| EP-1883645-B1 | DERIVATIVES OF 4-OR 5-AMINOSALICYLIC ACID | ANTIBE THERAPEUTICS INC (CA) | 2011-06-29 | — | — | EP | disclosed |
| US-20110130368-A1 | DERIVATIVES OF 4- OR 5-AMINOSALICYLIC ACID | ANTIBE THERAPEUTICS INC. (CA) | 2011-06-02 | — | — | US | disclosed |
| WO-2002039431-A2 | COMPOSITIONS AND METHODS RELATING TO PROSTATE SPECIFIC GENES AND PROTEINS | DIADEXUS, INC. (US) | 2002-05-16 | — | — | WO | disclosed |
| WO-2002036807-A2 | COMPOSITIONS AND METHODS RELATING TO BREAST SPECIFIC GENES AND PROTEINS | DIADEXUS, INC. (US) | 2002-05-10 | — | — | WO | disclosed |
| WO-2002036616-A2 | COMPOSITIONS AND METHODS RELATING TO BREAST SPECIFIC GENES AND PROTEINS | DIADEXUS, INC. (US) | 2002-05-10 | — | — | WO | disclosed |
| WO-2002036808-A2 | COMPOSITIONS AND METHODS RELATING TO PROSTATE SPECIFIC GENES AND PROTEINS | DIADEXUS, INC. (US) | 2002-05-10 | — | — | WO | disclosed |
| US-20020048763-A1 | Human genome-derived single exon nucleic acid probes useful for gene expression analysis | AMERSHAM PLC (GB) | 2002-04-25 | — | — | US | disclosed |
| US-20020048800-A1 | Myosin-like gene expressed in human heart and muscle | GE HEALTHCARE LIMITED (GB) | 2002-04-25 | — | — | US | disclosed |
| WO-2002026818-A2 | HUMAN NEDD-1 | AEOMICA, INT. (US) | 2002-04-04 | — | — | WO | disclosed |
| WO-2002024718-A1 | COMPOSITIONS AND METHODS RELATING TO PROSTATE SPECIFIC GENES AND PROTEINS | DIADEXUS, INC. (US) | 2002-03-28 | — | — | WO | disclosed |
| WO-2002024750-A2 | HUMAN KIDNEY TUMOR OVEREXPRESSED MEMBRANE PROTEIN 1 | AEOMICA, INC. (US) | 2002-03-28 | — | — | WO | disclosed |
| WO-2001092524-A2 | MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE | AEOMICA, INC. (US) | 2001-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130368-A1 | DERIVATIVES OF 4- OR 5-AMINOSALICYLIC ACID | CBS, SI, APC | EPHX2 1216/4885KDM4E 739/4885MAPT 3407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.